Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice

Circulation

Volumn 99, Issue 13, 1999, Pages 1726-1732

  Moulton, Karen S ^a,b   Heller, Eric ^c   Konerding, Moritz A ^d   Flynn, Evelyn ^a   Palinski, Wulf ^e   Folkman, Judah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Angiogenesis; Apolipoproteins; Atherosclerosis

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; HYPERLIPOPROTEINEMIA TYPE 3; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033528660     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.13.1726     Document Type: Article

References (28)

1. Barger AC, Beeuwkes R, Lainey L, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. N Engl J Med. 1984;310:175-177.
2. Koester W. Endarteritis and arteritis. Berl Klin Wochenschr. 1876;13: 454-455.
3. Zhang Y, Cliff WJ, Schoefl GI, Higgins G. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol. 1993; 143:164-172.
4. O'Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, Schwartz SM. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol. 1994;145:883-894.
5. Polverini PJ, Cotran RS, Gimbrone MA Jr, Unanue ER. Activated macrophages induce vascular proliferation. Nature. 1977;269:804-806.
6. Kaartinen M, Penttila A, Kovanen PT. Mast cells accompany microvessels in human coronary atheromas. Atherosclerosis. 1996; 123: 123-131.
7. Auerbach R, Sidky YA. Nature of the stimulus leading to lymphocyte-induced angiogenesis. J Immunol. 1979;123:751-754.
8. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, ICAM-1, and VCAM-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation. 1996;93: 672-682.
9. Paterson JC. Capillary rupture with intimal hemorrhage as a causative factor in coronary thrombosis. Arch Pathol. 1938;25:474-487.
10. Tenaglia AN, Peters KG, Sketch MH Jr, Annex BH. Neovascularization in atherectomy specimens from patients with unstable angina. Am Heart J. 1998;135:10-14.
11. Gross JL, Moscatelli D, Rifkin DB. Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc Natl Acad Sci USA. 1983;80:2623-2627.
12. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
13. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990;348:555-557.
14. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-407.
15. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
16. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Arterioscler Thromb. 1994;14:605-616.
17. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models. J Lipid Res. 1995;36:2320-2328.
18. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68: 231-240.
19. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
20. Dong ZM, Chapman S, Brown A, Frenette P, Hynes RO, Wagner DD. Combined role of P- and E-selectins in atherosclerosis. J Clin Invest. 1998;102:145-152.
21. Wolinsky H, Glagov S. A lamellar unit of aortic medial structure and function in mammals. Circ Res. 1967;20:99-111.
22. Torres Filho I, Leunig M, Yuan F, Intaglietta M, Jain R. Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc Natl Acad Sci U S A. 1994;91:2081-2085.
23. Budson AE, Ko L, Brasel C, Bischoff J. The angiogenesis inhibitor AGM-1470 selectively increases E-selectin. Biochem Biophys Res Commun. 1996;225:141-145.
24. Koyama H, Nishizawa Y, Hosoi M, Fukumoto S, Kogawa K, Shioi A, Morii H. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by PDGF and IGF-I. Circ Res. 1996;79:757-764.
25. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A. 1997; 94:6099-6103.
26. Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, Takuwa Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retino-blastoma gene product in vascular endothelial cells. Cancer Res. 1994; 54:3407-3412.
27. Brogi E, Winkles JA, Underwood R, Clinton SK, Alberts GF, Libby P. Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. J Clin Invest. 1993;92:2408-2418.
28. Couffinhal T, Kearney M, Witzenbichler B, Chen D, Murohara T, Losordo DW, Symes J, Isner JM. VEGF(VPF) in normal and atherosclerotic human arteries. Am J Pathol. 1997;150:1673-1685.